“…These results provide evidence that etodolac would not suppress the antitumor activity of paclitaxel. Furthermore, the slight antiproliferative effect of etodolac and its enhancement of the antiproliferative effect of paclitaxel in MDA-MB-468 cells observed in the present study is consistent with results of other basic studies showing that etodolac has antineoplastic effects against a variety (Kolluri et al, 2005;Khwaja et al, 2009), bladder (Okamoto et al, 2008), skin (Kapadia et al, 2010), and tongue carcinoma (Mishima et al, 2005), hepatoma (Behari et al, 2007), and pancreatic (Adachi et al, 2008) and blood cancer (Yasui et al, 2005;de Souza Thiago et al, 2009), as well as antimetastatic effects (Iwata et al, 2007;Benish et al, 2008;Tachimori et al, 2008). In addition, a clinical study showed that etodolac can provide secondary prevention of gastric cancer (Yanaoka et al, 2010).…”